НовостиBenzingaGuggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65 Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65 Benzinga 2026.10.06 12:02 (GMT+0) Открыть на Benzinga Другие новости